{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:05:14Z","timestamp":1775714714728,"version":"3.50.1"},"reference-count":39,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,2,28]]},"DOI":"10.2217\/fon-2018-0637","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T10:20:20Z","timestamp":1541067620000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Acalabrutinib and its Use in Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1080","volume":"15","author":[{"given":"Yasir","family":"Khan","sequence":"first","affiliation":[{"name":"UCI Medical Center, Orange, CA 92868, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"UCI Medical Center, Orange, CA 92868, USA"},{"name":"Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8"},{"key":"e_1_3_3_4_1","first-page":"440","volume-title":"ASCO-SEP Medical Oncology Self-Evaluation Program (5th Edition)","author":"Adjei AA","year":"2016","unstructured":"Adjei AA , AppelbaumFR, BaxiSet al. Chronic lymphocytic leukemia. In: ASCO-SEP Medical Oncology Self-Evaluation Program (5th Edition). MarteeL Hensley (Ed.). ASCO, Alexandria, VA, USA, 440\u2013443 (2016)."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200691"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.343"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12573"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_3_13_1","unstructured":"Imbruvica (ibrutinib) [package insert]. Pharmacyclics LLC and Janssen Biotech Inc. (2018)."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1591"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.642.642"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2032.2032"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0852-8"},{"key":"e_1_3_3_21_1","unstructured":"AstraZeneca Acerta Pharma . Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma [media release] (2017). www.acerta-pharma.com"},{"key":"e_1_3_3_22_1","volume-title":"American Society of Hematology (ASH) 59th Annual Meeting and Exposition","author":"Wang M","year":"2017","unstructured":"Wang M , RuleSA, ZinzaniPLet al. Efficacy and safety of acalabrutinib monotherapy in patients with relapased\/refractory mantle cell lymphoma in the Phase 2 ACE-LY-004 study. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. Atlanta, GA, USA, 9\u201312 December 2017 (Abstract 155)."},{"key":"e_1_3_3_23_1","unstructured":"Calquence (acalabrutinib) [package insert] . AstraZeneca Pharmaceuticals LP (2017)."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0250-9"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2596"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2624"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2920.2920"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.131"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0650"},{"key":"e_1_3_3_30_1","unstructured":"ClinicalTrials.gov . Acalabrutinib. (2018)."},{"key":"e_1_3_3_31_1","unstructured":"Clinicaltrials.gov. NCT02029443. (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029443"},{"issue":"1","key":"e_1_3_3_32_1","first-page":"151","article-title":"Acalabrutinib, a second-generation bruton tyrosine kinase (BTK) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL) [abstract no. S431]","volume":"101","author":"Wierda W","year":"2016","unstructured":"Wierda W , JonesJ, FurmanRet al. Acalabrutinib, a second-generation bruton tyrosine kinase (BTK) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL) [abstract no. S431]. Haematologica.101(Suppl. 1), 151 (2016).","journal-title":"Haematologica."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7521"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.638.638"},{"key":"e_1_3_3_35_1","first-page":"498","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the Phase 1\/2 ACE-CL-001 study","volume":"130","author":"Byrd JC","year":"2017","unstructured":"Byrd JC , WierdaWG, SchuhAet al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the Phase 1\/2 ACE-CL-001 study. Blood130, 498 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_36_1","unstructured":"ClinicalTrials.gov . NCT0226918 (2018)."},{"key":"e_1_3_3_37_1","first-page":"432","article-title":"Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-na\u00efve patients with chronic lymphocytic leukemia: the Phase 1b\/2 ACE-CL-003 study","volume":"130","author":"Woyach JA","year":"2017","unstructured":"Woyach JA , AwanFT, JianfarMet al. Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-na\u00efve patients with chronic lymphocytic leukemia: the Phase 1b\/2 ACE-CL-003 study. Blood130, 432 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_38_1","unstructured":"ClinicalTrials.gov . NCT02477696 (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477696"},{"key":"e_1_3_3_39_1","unstructured":"ClinicalTrials.gov . NCT02475681 (2018).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02475681"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818286"},{"key":"e_1_3_3_41_1","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd JC","year":"2007","unstructured":"Byrd JC , OwenR, O\u2019BrienSMet al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood130, 4326 (2007).","journal-title":"Blood"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:56Z","timestamp":1719125156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2,28]]}},"alternative-id":["10.2217\/fon-2018-0637"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0637","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}